Faculty, Staff and Student Publications
Language
English
Publication Date
10-9-2025
Journal
The Journal for ImmunoTherapy of Cancer
DOI
10.1136/jitc-2025-012401
PMID
41067879
PMCID
PMC12516986
PubMedCentral® Posted Date
10-9-2025
PubMedCentral® Full Text Version
Post-print
Abstract
Background: Recent data have suggested that germline genetic aberrations can affect outcomes in patients with large B-cell lymphoma (LBCL) treated with chimeric antigen receptor T-cell therapy (CART). However, a comprehensive analysis of germline determinants of response and toxicity after CART has not yet been described.
Methods: Genome-wide genotyping was performed in 170 patients with LBCL treated with standard of care axicabtagene ciloleucel. Polygenic risk score instruments for blood cell traits and inflammatory markers were obtained from the PGS Catalog and analyzed using PRSice-2. Exploratory gene-based and genome-wide association study analyses were performed. Genetic ancestry of the patients with LBCL was estimated using ADMIXTURE. Analysis was conducted to identify genetic risk of toxicity and efficacy endpoints.
Results: Increasing PRS for monocyte count was associated with increased risk of cytokine release syndrome of any grade (OR 2.49, 95% CI 1.18 to 5.25, p=0.016). Similarly, genetically predicted interleukin (IL)-1Rα and (IL)-27 levels were decreased (p=0.002) and increased (p=0.012) in patients with G3-4 day 30 cytopenia, respectively. The latter was also associated with variation in the hemophagocytic lymphohistiocytosis-related gene RAB27A (p=0.041). Genome-wide significant (p< 5×10-8) variants were identified in association with progression-free and overall survival, including SPOCK1, SLC28A2-AS1 and DUOX1. No significant differences in outcomes were observed based on ancestry, except for a decrease in risk for D30 G3-4 cytopenia for patients of European ancestry (p=0.026).
Conclusion: Germline genetic aberrations relevant to myeloid cell biology can predict toxicity and efficacy of CART in patients with LBCL. Elucidating such intrinsic determinants may help improve patient selection and develop strategies to enhance the therapeutic index of CART.
Keywords
Humans, Male, Female, Lymphoma, Large B-Cell, Diffuse, Middle Aged, Immunotherapy, Adoptive, Aged, Adult, Genome-Wide Association Study, Treatment Outcome, Genetic, Lymphoma, Chimeric antigen receptor - CAR, Macrophage, Cytokine release syndrome
Published Open-Access
yes
Recommended Citation
Strati, Paolo; Brandt, Amanda; Lionel, Anath C; et al., "Germline Determinants of Toxicity and Efficacy in Patients With Large B-cell Lymphoma Treated With Car T-cell Therapy" (2025). Faculty, Staff and Student Publications. 5833.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5833
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons